Novogen tumbles on termination of oncology candidate

7 April 2017
2019_biotech_test_vial_discovery_big

Australian biotech firm Novogen (ASX: NRT) has announced it will not continue development of its preclinical program ATM-3507 (anisina), causing its shareprice to tumble more than 20%.

The company’s scientific advisors decided a level of toxicity was observed that raised significant concern around the ability to provide a safe therapeutic dose.

Novogen chief executive James Garner said: “Our view is that the data that has been collected for Anisina does not, in aggregate, make it an appropriate candidate for clinical development.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology